Parents raising money for their daughter to have cancer treatment are overwhelmed by the generosity of people around the world.
A new campaign has been launched in the North East today to raise awareness of kidney and bladder cancer.
A charity says many children do not receive enough support when they miss school for cancer treatments.
A woman who watched her best friend and her aunt die from cancer said pain relief for patients should be improved.
Rozzie Joyce, from Hexham, Northumberland, was so distressed by the suffering she saw them endure, she has started a campaign to raise money for more research into pain relief.
Julie Harrison reports.
North East drinkers are being warned of the links between alcohol and cancer.
The message comes from the organisation Balance, which campaigns against alcohol misuse.
It says the more you drink, the more the risk increases.
It is the 30th anniversary of bone marrow transplants in the North East.
The Northern Centre for Cancer Care now has the second largest transplant programme in the country.
The procedure is used to treat patients with blood or bone marrow cancer. Katie Oakes reports.
A new drug to treat skin cancer has been given the go-ahead after being successfully trialled in Newcastle.
Erivedge tablets have shown evidence of shrinking tumours that are too big to be operated on.
Doctors at The Northern Centre for Cancer Care say it is a significant step forward in the fight against the most common type of cancer.
Jonny Blair reports.
A new drug to treat skin cancer is available after being successfully trialled in our region.
Erivedge tablets can be used to help shrink head and neck tumours, which are too big to be operated on.
Medical experts say it is a significant step forward in the fight against the most common type of cancer.
Jonny Blair reports.
From today a once-a-day pill, that was trialled in Newcastle, will be available for patients with a rare form of skin cancer
Patients with advanced basal cell carcinoma who are not suitable for surgery or radiotherapy could benefit from Erivedge.
Following clinical trials at the Northern Centre for Cancer Care in Newcastle it has been shown to shrink tumours.
The advanced form of the disease affects up to 700 people a year in the UK.
A breast cancer drug developed in Newcastle has been denied funding by the NHS. Perjeta is designed to extend the lives of patients.
Gregg Easteal reports.
– Mia Rosenblatt, head of policy and campaigns at Breast Cancer Campaign
It's disappointing that a drug that has shown real benefit to women with advanced HER-2 positive breast cancer has not received Nice approval.
However this is an interim decision and we hope that appropriate evidence to show its benefit can be provided and an agreement on cost made so that the NHS see this as a cost-effective treatment that could extend lives.
The National Institute for Health and Care Excellence (Nice) says it cannot recommend breast cancer drug pertuzumab for widespread use because clinical trial data could not predict how long the drug might extend people's lives for.
The organisation has now launched a consultation to hear the views of charities, patient groups and drug manufacturers.
Nice chief executive Sir Andrew Dillon said: "The appraisal committee couldn't be sure of the benefits of pertuzumab.
"The main clinical trial did not reflect current medical practice in the UK and despite the research data suggesting the treatment could help delay the growth and spread of the disease, the evidence was not robust enough to confirm for how long pertuzumab may actually extend people's lives."
A charity has expressed its "disappointment" over a decision not to provide a life-extending breast cancer drug on the NHS.
Breast Cancer Campaign said it hopes the draft decision from the National Institute for Health and Care Excellence (Nice) will be reversed before officials make a final determination on pertuzumab as a treatment for an advanced form of the disease.
The drug, also known as Perjeta, was widely welcomed when it was first introduced by manufacturers Roche.
The drug targets the HER-2 gene found in 20 percent of breast cancer patients. Trials have found that when used alongside the drug Herceptin and chemotherapy, patients live an average of six months longer without their cancer getting worse, compared with those just on Herceptin and chemotherapy.
At present, patients can access the drug through the Cancer Drugs Fund but it is not routinely available through the health service.